Clinical Trial

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

Study acronym: TARGET-DERM
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Protocol Amendment History 108 amendments
This ClinicalTrials.gov record has been amended 108 times since 2018-09-04; most recent amendment 2026-03-18.
Status change: Recruiting → Active, Not Recruiting 2026-03-18
Status change: Not Yet Recruiting → Recruiting 2019-01-07
Trial Details
NCT Number NCT03661866
Lead Sponsor Target PharmaSolutions, Inc.
Conditions Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria
Enrollment 15,000 participants
Start Date 2018-12-21
Primary Completion 2050-12 (estimated)
Study Completion 2050-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-20